Formycon

Formycon CROIC

The Cash Return on Invested Capital (CROIC) of Formycon (FYB.DE) as of Nov 22, 2026 is -10.79 %. In the previous year, Cash Return on Invested Capital (CROIC) was -11.25 % — a change of -4.09% (higher).

CROIC

-10.79 %

YoY

-4.09%

Last updated:

Cash Return on Invested Capital (CROIC) of Formycon is 2025 -10.79 % . Cash Return on Invested Capital (CROIC) of Formycon was 2024 -11.25 % . It decreases by -4.09% higher compared to the previous year.

The Formycon CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
32.31 EUR
Jan 1, 2019
-5.20 EUR
Jan 1, 2020
-7.92 EUR
Jan 1, 2021
-23.67 EUR
Jan 1, 2022
-11.27 EUR
Jan 1, 2023
-2.04 EUR
Jan 1, 2024
-11.25 EUR
Jan 1, 2025
-10.79 EUR
The Formycon CROIC history
YEARCROICYoY
-10.79 %-4.09%
-11.25 %+450.61%
-2.04 %-81.87%
-11.27 %-52.38%
-23.67 %+199.05%
-7.92 %+52.29%
-5.20 %-116.09%
32.31 %-279.31%
-18.02 %-9.76%
-19.97 %+5,718.54%
-0.34 %-87.44%
-2.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formycon Stock analysis

What does Formycon do? Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Formycon stock

Cash Return on Invested Capital (CROIC) of Formycon is -10.79 % in 2025.

Cash Return on Invested Capital (CROIC) of Formycon changed from -11.25 % to -10.79 %, representing a -4.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Formycon since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Formycon with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Formycon

All Key Metrics — Formycon